The sprint to advance a COVID-19 vaccine is hotly contested. More than 100 vaccines are in preclinical testing, according to GlobalData, while 23 companies have moved their candidates into clinical trials. Broadly, some eight different vaccine technologies are in clinical trials: mRNA, DNA plasmid, protein subunit, adenovirus-vectored, measles-vectored, vesicular stomatitis virus-vectored, adenovirus associated-vectored and inactivated virus vaccines. Seven companies have planned or ongoing Phase II/III studies: AstraZeneca, Inovio, Moderna, Novavax, Pfizer/BioNtech, Sinopharm and Sinovac
Scope
Snapshot of upcoming high-impact, catalytic events for COVID-19 vaccines
Insights investigative journalism related to COVID-19 vaccine development
Exclusive analysis of various vaccine technologies' prospects
Considerations for trial protocols and approvals
Key Highlights
Sixteen catalysts highlighted
Eight vaccine technologies in clinical trials discussed
Seven companies with planned or ongoing Phase II/III studies plus others in earlier-stage development analyzed
Five investigative articles on trial design requirements and launch considerations with an early EUA
Five to 12 experts cited per article
Reasons to Buy
Stay ahead of pipeline developments for COVID-19 vaccines
Obtain a snapshot of future, key clinical trial events
Access qualitative asset analysis based on talking to 5-12 KOLs about various vaccines in clinical trials
Leverage investigative journalism content on prospects for vaccine approvals and market uptake
